Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
T. Samukawa, T. Hamada, K. Mizuno, I. Higashimoto, H. Inoue (Kagoshima, Japan). The elevation serum napsin A in primary lung adenocarcinoma, compared with CEA. Eur Respir J 2012; 40: Suppl. 56, 1241

Member's Comments

No comment yet.

Related content which might interest you: Serum napsin A as a tumor marker for primary lung adenocarcinoma Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 CEA levels in the serum and induced sputum of lung cancer patients Source: Eur Respir J 2005; 26: Suppl. 49, 324s Year: 2005 Serum carcinoembryonic antigen (CEA) level as a predictive marker for distant metastasis in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006 Prognostic significance of three tumor markers (CA125, CEA, and TPA) in lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002 Clinical significance of CEA, NSE, CYFRA 21-1 in serum and pleural fluid for the diagnosis of malignant pleural effusion associated with primary lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 528s Year: 2004 An elevated serum level of cyfra 21 heralds poor outcome for operable bronchogenic cancer Source: Eur Respir J 2004; 24: Suppl. 48, 40s Year: 2004 Tumor markers (TM) CEA, CYFRA 21-1,MCA and NSE in pleural effusion(PE) at malignant mezothelioma and metastatic tumor of pleura Source: Eur Respir J 2002; 20: Suppl. 38, 439s Year: 2002 Serum tumor markers in lung cancer patients Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies Year: 2007 The correlation of serum tumor markers and distant metastasis in lung adenocarcinoma Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside Year: 2017 Neuron-specific enolase (NSE) serum level as a prognostic factor for tumor regression and survival in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 73s Year: 2002 Plasma D-dimer level and stage of primary lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 Evaluation of serum tumour markers in the lung cancer patients Source: Eur Respir J 2002; 20: Suppl. 38, 268s Year: 2002 Response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) according to their serum levels of chosen tumor markers (CYFRA 21-1 (CY21), CEA and NSE) Source: Eur Respir J 2001; 18: Suppl. 33, 377s Year: 2001 Serum neuron-specific enolase - a marker for disease extent and response to therapy of small-cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 The prognostic significance of circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide and neuron- specific enolase in patients with advanced non-small-cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Smoking status and serum NSE, as prognostic factors in adenocarcinoma of lung Source: Eur Respir J 2005; 26: Suppl. 49, 325s Year: 2005 Tumor markers in bronchial secretions and serum in patients with lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004 HER-2/neu overexpression in patients with lung carcinoma Source: Eur Respir J 2003; 22: Suppl. 45, 250s Year: 2003 Can high levels of serum tumor markers be useful in predicting the histologic type of lung cancer? Source: Eur Respir J 2004; 24: Suppl. 48, 77s Year: 2004 Is Cyfra 21-1 serum level predictive for the type of response to treatment or survival in locally advanced and metastatic non-small cell lung cancer (NSCLC)? Source: Eur Respir J 2004; 24: Suppl. 48, 76s Year: 2004